Serum Institute of India (SII) was continuing its trial works for making NOVAVAX in India. Paul who is the CEO of SII gave brief information to the ministry of health and family welfare (MOHFW) on Tuesday. He also said that they are on the brink of completion. In August 2020, SII announced that it had reached an agreement with the Pune-based Serum Institute of India to work together in the development and distribution of COVID-19 vaccines.
The result of NOVAVAX vaccine trials showed better improvement. The doses will be produced in India with the help of a US firm. The vaccine showed 90% of the desired results. The vaccine is much safe and effective. Due to its effective and safe nature, the NOVAVAX vaccine will be more helpful to society. NOVAVAX vaccine will be produced in large quantities by the SII in India So that it can be easily distributed all over the country. On May 5 by the filing of the clinical trial organization, SII conducted a phase II/III observer-blinded, randomized, and active-controlled study involving a group of about 1,600 participants over the age group of 18 to evaluate the safety of its Novavax’s vaccine in comparison with the Novavax SARS-CoV-2 rS.
Novavax is closing the gap of the needs of the global public for additional COVID-19 vaccines. Paul also suggested the process of vaccine trials in children. According to estimates put forward by the central government, shots up to 20 crores of the Novavax vaccine (that is about five crores per month)will be made available between September and December although these numbers may vary depending on the flexibility of SII’s to ramp up production. The Novavax vaccine, developed is a two-dose vaccine and due to the relative ease in storage also and transport makes it a good candidate for India. However, there are some concerns regarding the circulation and availability in various remote locations.
The SII will be supplying 20 crores of the vaccine between September and December 2021. The vaccination rate showed an increase of 26 crores on Tuesday. Paul also said that these will a breakthrough in the field of vaccination.